Increased circulating resistin is associated with insulin resistance, oxidative stress and platelet activation in type 2 diabetes mellitus

Summary

Resistin is an adipokine that promotes inflammation and insulin resistance by targeting several cells including platelets. We hypothesised that in type 2 diabetes (T2DM), resistin may foster in vivo oxidative stress, thromboxane-dependent platelet activation and platelet-derived inflammatory proteins release, key determinants of atherothrombosis. A cross-sectional comparison of circulating resistin, sCD40L, as a marker of platelet-mediated inflammation, asymmetric dimethylarginine (ADMA), endothelial dysfunction marker, Dickkopf (DKK)-1, reflecting the inflammatory interaction between platelets and endothelial cells, and urinary 8-iso-PGF_2α and 11-dehydro-TxB₂, reflecting in vivo lipid peroxidation and platelet activation, respectively, was performed between 79 T2DM patients and 30 healthy subjects. Furthermore, we investigated the effects of the α-glucosidase inhibitor acarbose and the PPARγ agonist rosiglitazone, targeting hyperglycaemia or insulin resistance, versus placebo, in 28 and 18 T2DM subjects, respectively. Age- and gender-adjusted serum resistin levels were significantly higher in patients than in controls. HOMA (β=0.266, p=0.017) and 11-dehydro-TXB₂ (β=0.354, p=0.002) independently predicted resistin levels. A 20-week treatment with acarbose was associated with significant reductions (p=0.001) in serum resistin, DKK-1, urinary 11-dehydro-TXB₂ and 8-iso-PGF_2α with direct correlations between the change in serum resistin and in other variables. A 24-week rosiglitazone treatment on top of metformin was associated with significant decreases in resistin, DKK-1, 11-dehydro-TXB₂ and 8-iso-PGF_2α, in parallel with HOMA decrease. In conclusion, resistin, antagonising insulin action in part through PPARγ activation, may favour insulin resistance and enhance oxidative stress, endothelial dysfunction and platelet activation. The adipokine-platelet interactions may be involved in platelet insulin resistance and their consequent pro-aggregatory phenotype in this setting.

Keywords

Diabetes mellitus - adipokine - insulin resistance - oxidative stress - platelet activation

• References

• 1 Santilli F, Formoso G, Sbraccia P. et al. Postprandial hyperglycaemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost 2010; 08: 828-837.
• 2 Davì G, Ciabattoni G, Consoli A. et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-229.
• 3 Santilli F, Davì G, Consoli A. et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 2006; 47: 391-397.
• 4 Lattanzio S, Santilli F, Liani R. et al. Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin. J Am Heart Assoc 2014; 03: e001000.
• 5 Santilli F, Simeone P, Liani R, Davì G. Platelets and diabetes mellitus. Prostaglandins Other Lipid Mediat 2015; 120: 28-39.
• 6 Basili S, Pacini G, Guagnano MT. et al. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 2006; 48: 2531-2538.
• 7 Falcon C, Pfliegler G, Deckmyn H, Vermylen J. The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem Biophys Res Commun 1988; 157: 1190-1196.
• 8 Trovati M, Mularoni EM, Burzacca S. et al. Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes 1995; 44: 1318-1322.
• 9 Steppan CM, Bailey ST, Bhat S. et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
• 10 Syed Ikmal SI, Zaman Huri H, Vethakkan SR, Wan Ahmad WA. Potential Biomarkers of Insulin Resistance and Atherosclerosis in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease. J Endocrinol 2013; 2013: 698567.
• 11 Chen BH, Song Y, Ding EL. et al. Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care 2009; 32: 329-334.
• 12 Abate N, Sallam HS, Rizzo M. et al. Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. Curr Pharm Des 2014; 20: 4961-4969.
• 13 Fontana A, Spadaro S, Copetti M. et al. Association between Resistin Levels and All-Cause and Cardiovascular Mortality. A New Study and a Systematic Review and Meta-Analysis. Plos One 2015; 10: e0120419.
• 14 Ortega Moreno L, Lamacchia O, Fontana A. et al. The combined effect of adiponectin and resistin on all-cause mortality in patients with type 2 diabetes: Evidence of synergism with abdominal adiposity. Atherosclerosis 2016; 250: 23-29.
• 15 Derosa G, D’Angelo A, Salvadeo SA. et al. Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. Biomed Pharmacother 2009; 63: 723-733.
• 16 American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care 2016; 39: S13-S22.
• 17 Chiasson JL, Josse RG, Gomis R. et al. STOPNIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002; 359: 2072-2077.
• 18 Khuu HM, Robinson CA, Goolsby K. et al. Evaluation of a fully automated high-performance liquid chromatography assay for hemoglobin A1c. Arch Pathol Lab Med 1999; 123: 763-7.
• 19 Matthews DR, Hosker JP, Rudenski AS. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
• 20 Davì G, Averna M, Catalano I. et al. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation 1992; 85: 1792-1798.
• 21 Wang Z, Ciabattoni G, Créminon C. et al. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther 1995; 275: 94-100.
• 22 Ciabattoni G, Maclouf J, Catella F. et al. Radioimmunoassay of 11-dehydro-thromboxane B2 in human plasma and urine. Biochim Biophys Acta 1987; 918: 293-297.
• 23 Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol 2012; 165: 622-632.
• 24 Ottobelli Chielle E, de Souza WM, da Silva TP. et al. Adipocytokines, inflammatory and oxidative stress markers of clinical relevance altered in young overweight/obese subjects. Clin Biochem 2016 pii: S0009–912000005–9.
• 25 Tokuyama Y, Osawa H, Ishizuka T. et al. Serum resistin level is associated with insulin sensitivity in Japanese patients with type 2 diabetes mellitus. Metabolism 2007; 56: 693-698.
• 26 Gharibeh MY, Al Tawallbeh GM, Abboud MM. et al. Correlation of plasma re-sistin with obesity and insulin resistance in type 2 diabetic patients. Diabetes Metab 2010; 36: 443-449.
• 27 Mojiminiyi OA. Abdella NA. Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus. Scand J Clin Lab Invest 2007; 67: 215-225.
• 28 Nieva-Vazquez A, Pérez-Fuentes R, Torres-Rasgado E. et al. Serum resistin levels are associated with adiposity and insulin sensitivity in obese Hispanic subjects. Metab Syndr Relat Disord 2014; 12: 143-148.
• 29 Maggio AB, Wacker J, Montecucco F. et al. Serum resistin and inflammatory and endothelial activation markers in obese adolescents. J Pediatr 2012; 161: 1022-1027.
• 30 De Luis DA, Gonzalez Sagrado M, Conde R. et al. Lack of association of serum resistin levels with metabolic syndrome criteria in obese female patients. Clin Biochem 2011; 44: 1280-1283.
• 31 Gómez-Ambrosi J, Catalán V, Rodríguez A. et al. Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as meta-bolically healthy. Diabetes Care 2014; 37: 2813-2821.
• 32 Rajala MW, Qi Y, Patel HR. et al. Regulation of resistin expression, circulating levels in obesity, diabetes, and fasting. Diabetes 2004; 53: 1671-1679.
• 33 Cabrera de León A, Almeida González D, González Hernández A. et al. Relationships between serum resistin, fat intake, serum lipid concentrations and adiposity in the general population. J Atheroscler Thromb 2014; 21: 454-462.
• 34 Benomar Y, Amine H, Crépin D. et al. Central Resistin/TLR4 Impairs Adiponectin Signalling, Contributing to Insulin and FGF21 Resistance. Diabetes 2016; 65: 913-926.
• 35 Kang YE, Kim JM, Joung KH. et al. The Roles of Adipokines, Proinflammatory Cytokines, and Adipose Tissue Macrophages in Obesity-Associated Insulin Resistance in Modest Obesity and Early Metabolic Dysfunction. PLoS One 2016 11e0154003.
• 36 Santilli F, Vazzana N, Liani R. et al. Platelet activation in obesity and metabolic syndrome. Obes Rev 2012; 13: 27-42.
• 37 Gerrits AJ, Gitz E, Koekman CA. et al. Induction of insulin resistance by the adi-pokines resistin, leptin, plasminogen activator inhibitor-1 and retinol binding protein 4 in human megakaryocytes. Haematologica 2012; 97: 1149-1157.
• 38 Filkova M, Haluzík M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol 2009; 133: 157-170.
• 39 Fliser D. Asymmetric dimethylarginine (ADMA): the silent transition from an _uraemic toxin_ to a global cardiovascular risk molecule. Eur Clin Invest 2005; 35: 71-79.
• 40 Verma S, Li SH, Wang CH. et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003; 108: 736-740.
• 41 Hu WL, Qian SB, Li JJ. Decreased C-reactive protein induced resistin production in human monocytes by simvastatin. Cytokine 2007; 40: 201-206.